| __timestamp | Regeneron Pharmaceuticals, Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 6795238 |
| Thursday, January 1, 2015 | 838526000 | 7454247 |
| Friday, January 1, 2016 | 1177697000 | 10345862 |
| Sunday, January 1, 2017 | 1320433000 | 16984203 |
| Monday, January 1, 2018 | 1556200000 | 16187290 |
| Tuesday, January 1, 2019 | 1834800000 | 9299233.54 |
| Wednesday, January 1, 2020 | 1346000000 | 19232000 |
| Friday, January 1, 2021 | 1824900000 | 23611000 |
| Saturday, January 1, 2022 | 2115900000 | 26700000 |
| Sunday, January 1, 2023 | 2631300000 | 28215000 |
| Monday, January 1, 2024 | 2954400000 |
Cracking the code
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Summit Therapeutics Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Regeneron has seen a steady increase in SG&A expenses, peaking at approximately $2.63 billion in 2023. This represents a fivefold increase from 2014, reflecting their aggressive expansion and investment in administrative capabilities. In contrast, Summit Therapeutics has maintained a more conservative approach, with SG&A expenses growing modestly from around $6.8 million in 2014 to $28.2 million in 2023. This strategic restraint highlights Summit's focus on lean operations. As the biotech industry continues to evolve, these contrasting strategies offer valuable insights into cost management and operational efficiency.
Selling, General, and Administrative Costs: Johnson & Johnson vs Regeneron Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Summit Therapeutics Inc.
Breaking Down SG&A Expenses: Sanofi vs Regeneron Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Genmab A/S
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing GSK plc and Summit Therapeutics Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Summit Therapeutics Inc. vs Viridian Therapeutics, Inc.